SINGLE-DOSE FOSFOMYCIN TROMETAMOL (MONURIL) VERSUS MULTIPLE-DOSE NORFLOXACIN - RESULTS OF A MULTICENTER STUDY IN FEMALES WITH UNCOMPLICATED LOWER URINARY-TRACT INFECTIONS

被引：24

作者：

DEJONG, Z

PONTONNIER, F

PLANTE, P

机构：

[1] Department of Urology, Rangueil University Hospital, Toulouse

来源：

UROLOGIA INTERNATIONALIS | 1991年 / 46卷 / 04期

关键词：

URINARY TRACT INFECTION; UNCOMPLICATED LOWER; FOSFOMYCIN TROMETAMOL; NORFLOXACIN;

D O I：

10.1159/000282164

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

The results of an open, randomized study comparing the efficacy and safety of Fosfomycin trometamol (Monuril), 3-gram single dose, and Norfloxacin (Noroxine 400), 400 mg twice daily for 5 days, are reported. Clinical and bacteriological assessments were performed before and 3-4 (short-term) and 25-30 days (long-term) after treatment. Only female patients with uncomplicated lower urinary tract infection were eligible for inclusion in the study: 33 cases were given Fosfomycin trometamol and 30 cases Norfloxacin. In the overall etiology, Escherichia coli (74% of the strains found), Proteus mirabilis (6%) and Klebsiella pneumoniae (6%) are highly predominant. With regard to bacteriological efficacy, the percentages of eradication in the two groups were similar: after the short-term test, 93.9% (31 of 33 patients) in the Fosfomycin trometamol group and 86.6% (26 of 30) in the Norfloxacin group, and after the long-term tests, 73.3% (22 of 30) in the Fosfomycin trometamol group and 77.89% (21 of 27) in the Norfloxacin group. There are no statistically significant differences. The duration of the reported side effects was significantly lower in the Fosfomycin trometamol group. The simplified dosage regimen (single dose) and its favorable benefit/risk ratio justifies the use of Fosfomycin trometamol as a treatment for uncomplicated urinary tract infections in female patients.

引用

页码：344 / 348

页数：5

共 19 条

[1]

Moroni M., Monuril in lower uncomplicated urinary tract infections in adults, Eur Urol, 13, pp. 101-104, (1987)

[2]

Newman M., Rufin F., Activity of Monuril in lower urinary tract infections due to Fosfomycin-resistant bacteria, Eur Urol, 13, pp. 105-107, (1987)

[3]

Grassi G., Modem trends in the treatment of lower urinary tract infections: Monuril as oral single-dose therapy, Eur Urol, 13, pp. 52-53, (1987)

[4]

Jackson E., Fowler F., Urinary tract infections in women, Urol Clin North Am, 13, pp. 673-683, (1986)

[5]

Dunnell K., Carturight A., Medicine Takers, Prescribes and Hoarders, pp. 90-95, (1972)

[6]

Greenwood D., Slack R., Short-course treatment of urinary tract infection, Chemoterapia, 5, pp. 244-248, (1986)

[7]

Madsen P.O., Nielsen K.T., Graversen P.H., Aztreonam: Critical evaluation of the first monobactam antibiotic in treatment of urinary tract infections, J Urol, 140, pp. 925-932, (1988)

[8]

Ronald A.R., Boutros P., Mourtada H., Bacteria localisation and response to single dose therapy in women, Jama, 235, pp. 1854-1856, (1976)

[9]

Savard-Fenton M., Fenton B.W., Relier L.B., Lauer B.A., Byyny R.L., Single-dose Amoxicillin therapy with follow-up urine culture: Effective initial management for acute uncomplicated urinary tract infections, Am J Med, 73, pp. 808-813, (1982)

[10]

Rubin R.H., Fang L.S.T., Jones S.R., Munford R.S., Slepack J.M., Varga P.A., Onheriber L., Hall C.L., Tolkoff-Rubin N.E., Single-dose Amoxicillin therapy for urinary tract infection: Multicenter trial using antibody-coated bacteria localization technique, Jama, 244, pp. 561-564, (1980)

← 1 2 →